You are here: Industry Insights > NTM

News List

Janssen, TenNor Enter NTM Research Pact contractpharma
January 19, 2021
To leverage TenNor’s multitargeting drug conjugation platform to discover new therapies to treat nontuberculous mycobacteria diseases.
RedHill Biopharma Initiates Study of RHB-204 for NTM Disease americanpharmaceuticalreview
December 08, 2020
RedHill Biopharma has initiated its Phase 3 study to evaluate the safety and efficacy of RHB-204 as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) ...
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease prnasia
November 23, 2020
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy.
RedHill Announces Orphan Drug Designation for NTM Infection Treatment americanpharmaceuticalreview
October 22, 2020
RedHill Biopharma announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.
Spero Receives Orphan Drug Designation for Nontuberculous Mycobacterial Treatment americanpharmaceuticalreview
March 12, 2020
Spero Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for oral SPR720 for the treatment of nontuberculous mycobacterial (NTM) infection.
Incidence of Nontuberculous Mycobacteria Lung Disease Rising drugs
December 26, 2019
The incidence and prevalence of nontuberculous mycobacterial (NTM) lung disease is increasing in the United States, according to a study published online in the Annals of the American Thoracic Society.
Spero Reports Preliminary Findings from SPR720 Trial americanpharmaceuticalreview
December 10, 2019
Spero Therapeutics announced preliminary findings from a Phase 1 first-in-human clinical trial of SPR720, its oral antimicrobial agent in development for the treatment of ...
Aradigm secures SBIR grant to investigate use of Linhaliq and Lipoquin for PNTM treatment pharmaceutical-technology
August 17, 2017
Aradigm has secured a small business initiative research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH). The two-year grant will be used by the company to investigate the tr
RedHill Biopharma announces QIDP Fast-Track Designation granted by FDA to RHB-104 for Nontuberculous pharmaasia
February 06, 2017
RedHill Biopharma Ltd has announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) infections.
RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous b3cnewswire
January 13, 2017
RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection